Prospective therapies for mucopolysaccharidoses

Bibliography

• Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta 2009;1793(4):684-96
   PubMed Web of Science ®Google Scholar
• Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 2011;50(Suppl 5):v4-12
   PubMed Web of Science ®Google Scholar
• Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, et al. editors. The online metabolic and molecular basis of inherited disease. McGraw-Hill; New York
   Google Scholar
• Coutinho MF, Lacerda L, Alves S. Glycosaminoglycan storage disorders: a review. Biochem Res Int 2012;2012:471325
   PubMedGoogle Scholar
• Opoka-Winiarska V, Jurecka A, Emeryk A, Tylki-Szymanska A. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation. Osteoarthritis Cartilage 2013;21(12):1813-23
   PubMed Web of Science ®Google Scholar
• Walkley SU. Pathogenic cascades in lysosomal disease-Why so complex? J Inherit Metab Dis 2009;32(2):181-9
   PubMed Web of Science ®Google Scholar
• Mangas M, Nogueira C, Prata MJ, et al. Molecular analysis of mucopolysaccharidosis type IIIB in Portugal: evidence of a single origin for a common mutation (R234C) in the Iberian Peninsula. Clin Genet 2008;73(3):251-6
   PubMed Web of Science ®Google Scholar
• Coutinho MF, Matos L, Alves S. From bedside to cell biology: a century of history on lysosomal dysfunction. Gene 2015;555(1):50-8
   PubMed Web of Science ®Google Scholar
• Oussoren E, Brands MM, Ruijter GJ, et al. Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options. Biochim Biophys Acta 2011;1812(11):1542-56
   PubMed Web of Science ®Google Scholar
• Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science 2011;332(6036):1429-33
   PubMed Web of Science ®Google Scholar
• Settembre C, Ballabio A. Cell metabolism: autophagy transcribed. Nature 2014;516(7529):40-1
   PubMed Web of Science ®Google Scholar
• Hollak CE, Wijburg FA. Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis 2014;37(4):587-98
   PubMed Web of Science ®Google Scholar
• Clarke LA, Winchester B, Giugliani R, et al. Biomarkers for the mucopolysaccharidoses: discovery and clinical utility. Mol Genet Metab 2012;106(4):395-402
   PubMed Web of Science ®Google Scholar
• Lachmann R, Schoser B. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis 2013;8(1):160
   PubMedGoogle Scholar
• Kakkis ED. Enzyme replacement therapy for the mucopolysaccharide storage disorders. Expert Opin Investig Drugs 2002;11(5):675-85
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Almeciga-Diaz CJ, Montano AM, et al. Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab 2015;114(2):94-109
   PubMed Web of Science ®Google Scholar
• Beck M, Braun S, Coerdt W, et al. Fetal presentation of Morquio disease type A. Prenat Diagn 1992;12(12):1019-29
   PubMed Web of Science ®Google Scholar
• Martin JJ, Ceuterick C. Prenatal pathology in mucopolysaccharidoses: a comparison with postnatal cases. Clin Neuropathol 1983;2(3):122-7
   PubMed Web of Science ®Google Scholar
• Ohashi A, Montano AM, Colon JE, et al. Sacral dimple: incidental findings from newborn evaluation. Mucopolysaccharidosis IVA disease. Acta Paediatr 2009;98(5):768-9.910-12
   PubMed Web of Science ®Google Scholar
• Crawley AC, Niedzielski KH, Isaac EL, et al. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J Clin Invest 1997;99(4):651-62
   PubMed Web of Science ®Google Scholar
• Dierenfeld AD, McEntee MF, Vogler CA, et al. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med 2010;2(60):60ra89
   PubMed Web of Science ®Google Scholar
• Baldo G, Mayer FQ, Martinelli BZ, et al. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Mol Genet Metab 2013;109(1):33-40
   PubMed Web of Science ®Google Scholar
• Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics 2010;125(1):e183-7
   PubMed Web of Science ®Google Scholar
• Tylki-Szymanska A, Jurecka A, Zuber Z, et al. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: 3-year follow-up. Acta Paediatr 2012;101(1):e42-7
   PubMed Web of Science ®Google Scholar
• Tajima G, Sakura N, Kosuga M, et al. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings. Mol Genet Metab 2013;108(3):172-7
   PubMed Web of Science ®Google Scholar
• McGill JJ, Inwood AC, Coman DJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age–a sibling control study. Clin Genet 2010;77(5):492-8
   PubMed Web of Science ®Google Scholar
• Sands MS, Barker JE, Vogler C, et al. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab Invest 1993;68(6):676-86
   PubMed Web of Science ®Google Scholar
• Soper BW, Lessard MD, Vogler CA, et al. Nonablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency. Blood 2001;97(5):1498-504
   PubMed Web of Science ®Google Scholar
• Pievani A, Azario I, Antolini L, et al. Neonatal bone marrow transplantation prevents bone pathology in a mouse model of mucopolysaccharidosis type I. Blood 2015;125(10):1662-71
   PubMed Web of Science ®Google Scholar
• Ponder KP, O’Malley TM, Wang P, et al. Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats. Mol Ther 2012;20(5):898-907
   PubMed Web of Science ®Google Scholar
• Macsai CE, Derrick-Roberts AL, Ding X, et al. Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII. Mol Genet Metab 2012;106(2):202-13
   PubMed Web of Science ®Google Scholar
• de Duve C. From cytases to lysosomes. Fed Proc 1964;23:1045-9
   PubMedGoogle Scholar
• Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet 2012;13:307-35
   PubMed Web of Science ®Google Scholar
• Jurecka A, Tylki-Szymanska A. Enzyme replacement therapy: lessons learned and emerging questions. Expert Opin Orphan drugs 2015;3(3):1-13
   Google Scholar
• Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab 2014;111(2):63-72
   PubMed Web of Science ®Google Scholar
• Vogler C, Levy B, Galvin NJ, et al. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res 1999;45(6):838-44
   PubMed Web of Science ®Google Scholar
• Vogler C, Levy B, Grubb JH, et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A 2005;102(41):14777-82
   PubMed Web of Science ®Google Scholar
• Burrow TA, Hopkin RJ, Leslie ND, et al. Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr 2007;19(6):628-35
   PubMed Web of Science ®Google Scholar
• Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther 2012;6:81-106
   PubMed Web of Science ®Google Scholar
• Fox JE, Volpe L, Bullaro J, et al. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab 2015;114(2):203-8
   PubMed Web of Science ®Google Scholar
• Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968;162(3853):570-2
   PubMed Web of Science ®Google Scholar
• Lund TC. Hematopoietic stem cell transplant for lysosomal storage diseases. Pediatr Endocrinol Rev 2013;11(Suppl 1):91-8
   PubMedGoogle Scholar
• Parenti G, Pignata C, Vajro P, Salerno M. New strategies for the treatment of lysosomal storage diseases (review). Int J Mol Med 2013;31(1):11-20
   PubMed Web of Science ®Google Scholar
• Hobbs JR, Hugh-Jones K, Barrett AJ, et al. Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981;2(8249):709-12
   PubMed Web of Science ®Google Scholar
• De Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 2011;6:55
   PubMed Web of Science ®Google Scholar
• Peters C, Balthazor M, Shapiro EG, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996;87(11):4894-902
   PubMed Web of Science ®Google Scholar
• Peters C, Shapiro EG, Anderson J, et al. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. the storage disease collaborative study group. Blood 1998;91(7):2601-8
   PubMed Web of Science ®Google Scholar
• Boelens JJ, Aldenhoven M, Purtill D, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood 2013;121(19):3981-7
   PubMed Web of Science ®Google Scholar
• Aldenhoven M, Wynn RF, Orchard PJ, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 2015;125(13):2164-72
   PubMed Web of Science ®Google Scholar
• Polgreen LE, Tolar J, Plog M, et al. Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;41(12):1005-11
   PubMed Web of Science ®Google Scholar
• Coppa GV, Gabrielli O, Zampini L, et al. Bone marrow transplantation in Hunter syndrome. J Inherit Metab Dis 1995;18(1):91-2
   PubMed Web of Science ®Google Scholar
• Coppa GV, Gabrielli O, Zampini L, et al. Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): two-year follow-up of the first Italian patient and review of the literature. Pediatr Med Chir 1995;17(3):227-35
   PubMedGoogle Scholar
• McKinnis EJ, Sulzbacher S, Rutledge JC, et al. Bone marrow transplantation in Hunter syndrome. J Pediatr 1996;129(1):145-8
   PubMed Web of Science ®Google Scholar
• Vellodi A, Young E, Cooper A, et al. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999;22(5):638-48
   PubMed Web of Science ®Google Scholar
• Peters C, Krivit W. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome). Bone Marrow Transplant 2000;25(10):1097-9
   PubMed Web of Science ®Google Scholar
• Boelens JJ, Prasad VK, Tolar J, et al. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am 2010;57(1):123-45
   PubMed Web of Science ®Google Scholar
• Tanaka A, Okuyama T, Suzuki Y, et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab 2012;107(3):513-20
   PubMed Web of Science ®Google Scholar
• Patel P, Suzuki Y, Tanaka A, et al. Impact of enzyme replacement therapy and hematopoietic stem cell therapy on growth in patients with hunter syndrome. Mol Genet Metab Rep 2014;1:184-96
   PubMedGoogle Scholar
• Tanjuakio J, Suzuki Y, Patel P, et al. Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation. Mol Genet Metab 2015;114(2):161-9
   PubMed Web of Science ®Google Scholar
• Giugliani R, Brusius-Facchin AC, Fishinger Moura de Souza C, et al. Diagnosis and therapy options in mucopolysaccharidosis type II (Hunter syndrome). Expert Opin Orphan Drugs 2014;3(2):141-50
   Web of Science ®Google Scholar
• Gungor N, Tuncbilek E. Sanfilippo disease type B. A case report and review of the literature on recent advances in bone marrow transplantation. Turk J Pediatr 1995;37(2):157-63
   PubMed Web of Science ®Google Scholar
• Sivakumur P, Wraith JE. Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J Inherit Metab Dis 1999;22(7):849-50
   PubMed Web of Science ®Google Scholar
• Vellodi A, Young E, New M, et al. Bone marrow transplantation for Sanfilippo disease type B. J Inherit Metab Dis 1992;15(6):911-18
   PubMed Web of Science ®Google Scholar
• de Ruijter J, Valstar MJ, Wijburg FA. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. Curr Pharm Biotechnol 2011;12(6):923-30
   PubMed Web of Science ®Google Scholar
• Chinen Y, Higa T, Tomatsu S, et al. Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol Genet Metab Rep 2014;1:31-41
   PubMedGoogle Scholar
• Vantyghem MC, Cornillon J, Decanter C, et al. Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation. Orphanet J Rare Dis 2014;9:162
   PubMed Web of Science ®Google Scholar
• Velardi E, Dudakov JA, van den Brink MR. Clinical strategies to enhance thymic recovery after allogeneic hematopoietic stem cell transplantation. Immunol Lett 2013;155(1-2):31-5
   PubMed Web of Science ®Google Scholar
• Cox-Brinkman J, Boelens JJ, Wraith JE, et al. Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant 2006;38(1):17-21
   PubMed Web of Science ®Google Scholar
• Valayannopoulos V, de Blic J, Mahlaoui N, et al. Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation. Pediatrics 2010;126(5):e1242-7
   PubMed Web of Science ®Google Scholar
• Eisengart JB, Rudser KD, Tolar J, et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr 2013;162(2):375-80e1
   PubMed Web of Science ®Google Scholar
• Dunder U, Kaartinen V, Valtonen P, et al. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J 2000;14(2):361-7
   PubMed Web of Science ®Google Scholar
• Matzner U, Herbst E, Hedayati KK, et al. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum Mol Genet 2005;14(9):1139-52
   PubMed Web of Science ®Google Scholar
• Marshall NR, Hassiotis S, King B, et al. Delivery of therapeutic protein for prevention of neurodegenerative changes: comparison of different CSF-delivery methods. Exp Neurol 2015;263:79-90
   PubMed Web of Science ®Google Scholar
• Kakkis E, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 2004;83(1-2):163-74
   PubMed Web of Science ®Google Scholar
• Savas PS, Hemsley KM, Hopwood JJ. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol Genet Metab 2004;82(4):273-85
   PubMed Web of Science ®Google Scholar
• Auclair D, Finnie J, Walkley SU, et al. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatr Res 2012;71(1):39-45
   PubMed Web of Science ®Google Scholar
• Calias P, Papisov M, Pan J, et al. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One 2012;7(1):e30341
   PubMed Web of Science ®Google Scholar
• Munoz-Rojas MV, Vieira T, Costa R, et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 2008;146A(19):2538-44
   PubMed Web of Science ®Google Scholar
• Munoz-Rojas MV, Horovitz DD, Jardim LB, et al. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. Mol Genet Metab 2010;99(4):346-50
   PubMed Web of Science ®Google Scholar
• Muenzer J, Hendriksz CJ, Fan Z, et al. A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010;37(1):13-25
   PubMed Web of Science ®Google Scholar
• Boado RJ, Zhang Y, Zhang Y, et al. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug Chem 2008;19(3):731-9
   PubMed Web of Science ®Google Scholar
• Schiffmann R. Therapeutic approaches for neuronopathic lysosomal storage disorders. J Inherit Metab Dis 2010;33(4):373-9
   PubMed Web of Science ®Google Scholar
• Boado RJ, Ka-Wai Hui E, Zhiqiang Lu J, Pardridge WM. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. Biotechnol Bioeng 2014;111(11):2317-25
   PubMed Web of Science ®Google Scholar
• Boado RJ, Lu JZ, Hui EK, Pardridge WM. Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells. Mol Pharm 2014;11(8):2928-34
   PubMed Web of Science ®Google Scholar
• Weinreb NJ. Oral small molecule therapy for lysosomal storage diseases. Pediatr Endocrinol Rev 2013;11(Suppl 1):77-90
   PubMedGoogle Scholar
• Jakobkiewicz-Banecka J, Piotrowska E, Narajczyk M, et al. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 2009;16:26
   PubMed Web of Science ®Google Scholar
• Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, et al. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 2006;14(7):846-52
   PubMed Web of Science ®Google Scholar
• Moskot M, Montefusco S, Jakobkiewicz-Banecka J, et al. The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activation. J Biol Chem 2014;289(24):17054-69
   PubMed Web of Science ®Google Scholar
• Friso A, Tomanin R, Salvalaio M, Scarpa M. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br J Pharmacol 2010;159(5):1082-91
   PubMed Web of Science ®Google Scholar
• Malinowska M, Wilkinson FL, Bennett W, et al. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol Genet Metab 2009;98(3):235-42
   PubMed Web of Science ®Google Scholar
• Malinowska M, Wilkinson FL, Langford-Smith KJ, et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010;5(12):e14192
   PubMed Web of Science ®Google Scholar
• Piotrowska E, Jakobkiewicz-Banecka J, Wegrzyn G. Different amounts of isoflavones in various commercially available soy extracts in the light of gene expression-targeted isoflavone therapy. Phytother Res 2010;24(Suppl 1):S109-13
   PubMed Web of Science ®Google Scholar
• Arfi A, Richard M, Gandolphe C, Scherman D. Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J Inherit Metab Dis 2010;33(1):61-7
   PubMed Web of Science ®Google Scholar
• Piotrowska E, Jakóbkiewicz-Banecka J, Tylki-Szymanska A, et al. Genistein-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open label, pilot study in 10 pediatric patients. Curr Ther Res Clin Exp 2008;69:166-79
   PubMed Web of Science ®Google Scholar
• Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A, et al. Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 2011;17(4):CR196-202
   PubMed Web of Science ®Google Scholar
• Delgadillo V, O’Callaghan Mdel M, Artuch R, et al. Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 2011;34(5):1039-44
   PubMed Web of Science ®Google Scholar
• De Ruijter J, Valstar MJ, Narajczyk M, et al. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 2012;71(1):110-20
   PubMed Web of Science ®Google Scholar
• Marucha J, Tylki-Szymanska A, Jakobkiewicz-Banecka J, et al. Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT). Am J Med Genet A 2011;155A(9):2257-62
   PubMed Web of Science ®Google Scholar
• Otomo T, Hossain MA, Ozono K, Sakai N. Genistein reduces heparan sulfate accumulation in human mucolipidosis II skin fibroblasts. Mol Genet Metab 2012;105(2):266-9
   PubMed Web of Science ®Google Scholar
• Beck M. Enzyme replacement and gene therapy for mucopolysaccharidoses: current progress and future directions. Expert Opin Orphan Drugs 2015;3(4):433-44
   Web of Science ®Google Scholar
• Ortolano S, Vieitez I, Navarro C, Spuch C. Treatment of lysosomal storage diseases: recent patents and future strategies. Recent Pat Endocr Metab Immune Drug Discov 2014;8(1):9-25
   PubMedGoogle Scholar
• Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008;118(9):3132-42
   PubMed Web of Science ®Google Scholar
• Wolf DA, Banerjee S, Hackett PB, et al. Gene therapy for neurologic manifestations of mucopolysaccharidoses. Expert Opin Orphan Drugs 2015;12(2):283-96
   Web of Science ®Google Scholar
• Aronovich EL, Hackett PB. Lysosomal storage disease: gene therapy on both sides of the blood-brain barrier. Mol Genet Metab 2015;114(2):83-93
   PubMed Web of Science ®Google Scholar
• Tardieu M, Zerah M, Husson B, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther 2014;25(6):506-16
   PubMed Web of Science ®Google Scholar
• Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 2007;121(1):1-22
   PubMed Web of Science ®Google Scholar
• Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004;27(3):385-410
   PubMed Web of Science ®Google Scholar
• Treacy EP. Treatment of genetic disease. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, et al. editors. The online metabolic and molecular basis of inherited disease. McGraw-Hill; New York: 1-10
   Google Scholar
• Boustany RM. Lysosomal storage diseases–the horizon expands. Nat Rev Neurol 2013;9(10):583-98
   PubMed Web of Science ®Google Scholar
• Boyd RE, Lee G, Rybczynski P, et al. Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem 2013;56(7):2705-25
   PubMed Web of Science ®Google Scholar
• Schueler UH, Kolter T, Kaneski CR, et al. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis 2004;27(5):649-58
   PubMed Web of Science ®Google Scholar
• Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 2009;1(5):268-79
   PubMed Web of Science ®Google Scholar
• Feldhammer M, Durand S, Pshezhetsky AV. Protein misfolding as an underlying molecular defect in mucopolysaccharidosis III type C. PLoS One 2009;4(10):e7434
   PubMed Web of Science ®Google Scholar
• Ficko-Blean E, Stubbs KA, Nemirovsky O, et al. Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB. Proc Natl Acad Sci USA 2008;105(18):6560-5
   PubMed Web of Science ®Google Scholar
• Zhao KW, Neufeld EF. Purification and characterization of recombinant human alpha-N-acetylglucosaminidase secreted by Chinese hamster ovary cells. Protein Expr Purif 2000;19(1):202-11
   PubMed Web of Science ®Google Scholar
• Brooks DA, Muller VJ, Hopwood JJ. Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol Med 2006;12(8):367-73
   PubMed Web of Science ®Google Scholar
• Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 2013;64:407-25
   PubMed Web of Science ®Google Scholar
• Bartolomeo R, Polishchuk EV, Volpi N, et al. Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI. J Inherit Metab Dis 2013;36(2):363-71
   PubMed Web of Science ®Google Scholar
• Platt FM, Boland B, van der Spoel AC. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol 2012;199(5):723-34
   PubMed Web of Science ®Google Scholar
• Clarke LA. Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator. Rheumatology (Oxford) 2011;50(Suppl 5):v13-18
   PubMed Web of Science ®Google Scholar
• Shapiro IM, Layfield R, Lotz M, et al. Boning up on autophagy: the role of autophagy in skeletal biology. Autophagy 2014;10(1):7-19
   PubMed Web of Science ®Google Scholar